Home › Compare › WINKF vs ABBV
WINKF yields 11695.91% · ABBV yields 3.06%● Live data
📍 WINKF pulled ahead of the other in Year 1
Combined, WINKF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WINKF + ABBV for your $10,000?
Windfall Geotek Inc. develops platforms for the mining sector. The company offers computer aided resource detection system, a platform to analyze digital data sets of georeferenced historical exploration data, including geological, geochemical, geophysical, structural, and digital elevation data; and data mining services. It also acquires, explores for, and develops mineral resource properties in Québec. The company has an option agreement to hold 90% undivided interest in the Chapais project that comprises 36 claims located in Quebec; and 95% undivided interest in the Corallen Lake property that comprises 348 claims. It also owns 5,240 claims in the province of Ontario; 1,078 claims in the province of Quebec; and 11 claims in the province of New Brunswick. The company was formerly known as Albert Mining Inc. and changed its name to Windfall Geotek Inc. in October 2019. Windfall Geotek Inc. was incorporated in 1996 and is headquartered in Brossard, Canada.
Full WINKF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.